PPARG and breast cancer: In leukemia, lymphoma,and myeloma cells, exposure to rosiglitazone, 15d-PGJ2, orCDDO in combination with the RXR agonist, LG100268, or the retinoic acidreceptor (RAR) agonist, all transretinoic acid, augmented the growth-inhibitoryeffects in these cells [55].In agreement, treatment of breast cancer cells with another RXR selectiveligand, AGN194204, and the PPARγ ligand γ-linolenicacid showed an additive growth inhibitory response [65].Thus, combining retinoids with PPAR ligands may prove to be a successfultreatment in some cancers.